Figure 1.
Figure 1. PFS according to best response to nivolumab in patients with rel/ref HL enrolled on the CheckMate 205 study. Reprinted from Armand et al10 with permission.

PFS according to best response to nivolumab in patients with rel/ref HL enrolled on the CheckMate 205 study. Reprinted from Armand et al10  with permission.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal